The pharmacokinetics of habekacin, a new semisynthetic aminoglycoside antibiotic, were investigated in six healthy subjects and 25 uremic patients (six of whom were on hemodialysis) after administration of a single 3-mg/kg dose. Six healthy subjects received the 3-mg/kg dose both intramuscularly (i.m.) and intravenously (i.v.) (1-h infusion). Uremic patients were given the 3-mg/kg dose as an i.m. injection, except for the hemodialysis patients, who received the dose as a 1-h i.v. infusion. Afther the i.m. injection, the peak concentrations in serum were higher and the times to peak levels were longer in patients with renal impairment than in healthy subjects. The elimination half-life in serum increased in relation to the degree of renal impairment, from 2 h in normal subjects to 32 h in patients with creatinine clearances of less than 10 ml/min.
Habekacin [1-N-(S)-4 amino-2-hydroxybutyryl dibekacin]
is a new semisynthetic aminoglycoside antibiotic that is obtained by acylation of dibekacin in a reaction analogous to that used to produce amikacin (3) . The antibacterial activity of habekacin was roughly comparable to that of amikacin against Pseudomonas aeruginosa and several gentamicinand tobramycin-resistant organisms (A. Thabaut 206, 1985) . Resistance patterns of both antibiotics were found to be similar (8) . Like other aminoglycoside antibiotics, habekacin is excreted almost exclusively in urine as the active compound by glomerular filtration and tubular reabsorption. Therefore, it was essential to investigate the pharmacokinetic properties of habekacin in patients with various degrees of renal insufficiency.
MATERIALS AND METHODS
Subjects. Thirty-one subjects were selected for the study after informed written consent was obtained and approval was given by the Ethical Comittee, University of Rouen. A total of 6 subjects had normal renal function, and 25 subjects, 6 of whom were hemodialysis patients, had chronic renal impairment of various degrees. None of the subjects received any antibiotic in the month preceding the study, and none of them had a documented history of drug allergy.
The 25 patients with chronic renal failure (age range, 26 to 76 years; weight range, 43 to 92 kg) were divided into the following four groups on the basis of glomerular filtration rate, as determined by endogenous creatinine clearance (CLCR): group 1, mild renal impairment (n = 6; CLCR, > 30 ml/min); group 2, moderate renal impairment (n = 7; 10 < CLCR < 30 ml/min); group 3, severe renal impairment (n = 6; CLCR, < 10 ml/min); group 4, hemodialysis patients (n = 6). The physical characteristics of the subjects are given in infusion. In the study of hemodialysis patients, the 3-mg/kg i.v. dose of habekacin was administered 1 h prior to the beginning of the dialysis session. Blood samples were drawn at time 0 (before the infusion), 1 h (at the end of infusion, which was the beginning of dialysis), 1.5 h, 2 h, and each hour thereafter up to the end of the session, which lasted 4 to 5 h. Coil dialyzers (2308 CF 1511; Travenol, Maurepas, France) with single-pass dialysis were used. The blood flow rate was 300 ml/min, and the dialysate flow rate was 500 ml/min. Antibiotic assay. Blood was collected in nonheparinized tubes and allowed to clot at room temperature. Serum and urine samples were stored frozen at -80°C until assay.
Habekacin concentrations in serum and urine were measured by fluorescence polarization immunoassay (FPIA) with an analyzer (TDX; Abbott Laboratories, North Chi-ANTIMICROB. AGENTS CHEMOTHER. Creatinine concentrations in serum and urine were determined by the colorimetric method described previously (1) . Pharmacokinetic analysis. After the i.m. injection, the habekacin concentration in serum-time curves was best described by a two-compartment model, with first-order absorption and elimination. The linear least-squares regression method was used to determine the terminal elimination phase, and the absorption phase was estimated by using the method of residuals (Apple II personal computer). The following pharmacokinetic data of habekacin were calculated by using the equations described by Gibaldi (Table 2) .
Patients with chronic renal impairment. Representative mean graphs of the serum concentration-time curves after the 3-mg/kg dose was administered to subjects with normal renal function and to uremic patients from each group are shown in Fig. 1 CLT/F = 1.43 CLR + 3.75 [r = 0.997]) provided a basis for dosage adjustment in subjects with renal function itnpairment. Thus, we recommend injection of a 3-mg/kg habekacin dose as the loading dose in all patients. In uremic patients, the habekacin t1/2 could be evalhated from the following relationship: t1/2 (in hours) = 0.05 x blood creatinine (p.mol/liter). We propose injection of half the dose (i.e., 1.5 mg/kg) every t1/2 (t1/2 was calculated from the relationship described above). These schedules should be checked and adjusted, however, and the antibiotic concentrations in serum should be determined regularly to maintain effective and nontoxic levels in serum during treatment.
